Isis's new approach to cardiovascular disease shows early promise
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals is planning to conduct a Phase II proof-of-concept study next year, evaluating the efficacy of its candidate cardiovascular therapeutic, ISIS-APOCIIIRx, after the product was found to lower levels of apolipoprotein C-III (apoC-III) protein and triglycerides in a Phase I trial.